Phase 3 Readout~month
Phase 3 Topline: EPIK-B5: A Phase III, Randomized, Double-blind, Placebo-controlled Study of Alpelisib in Combination
- Company
- Novartis AG (NVS)
- Drug
- alpelisib
- Indication
- Breast Cancer
Other upcoming events for NVS
Phase 3 ReadoutPhase 3 Topline: A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to De
Phase 2 StartPhase 2 Start: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2 Study to Investigate the Efficac
Phase 2 StartPhase 2 Start: Open-label, Phase I/II Study to Evaluate Safety and Efficacy of Asciminib With Chemotherapy Followed
Phase 3 ReadoutPhase 3 Topline: A Randomized, Controlled, Open Label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 V
Phase 3 ReadoutPhase 3 Topline: PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Cha
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.